Innovative CAR Therapies CARsgen is actively developing next-generation CAR T-cell therapies targeting hematologic malignancies and solid tumors, offering opportunities to collaborate on cutting-edge treatment solutions and expand market reach.

Strategic Industry Presence Participation in major industry events such as EHA, ASCO, and ESMO demonstrates CARsgen’s commitment to advancing its pipeline and provides channels for introducing new therapies and establishing key partnerships.

Robust Platform Development With proprietary platforms like THANK-u Plus and ongoing product launches, CARsgen is positioned to meet increasing demand for innovative, safe, and cost-effective CAR T-cell treatments, opening avenues for partnerships in manufacturing and technology licensing.

Growing Financial Capacity With a funding of 186 million USD and revenue estimates between 50 and 100 million USD, CARsgen is expanding its operations and clinical trials, creating potential sales opportunities in medical supplies, accessories, and supporting infrastructure.

Global Clinical Footprint Active clinical trial activities across China and the U.S., including collaborations and presentations at international conferences, suggest a conducive environment for partnerships in clinical development, diagnostics, and post-market surveillance services.